Literature DB >> 23038217

Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy.

Grace D Kinabo1, Mirte Sprengers, Levina J Msuya, Aisa M Shayo, Henri van Asten, Wil M V Dolmans, Andre J A M van der Ven, Adilia Warris.   

Abstract

OBJECTIVE: Highly active antiretroviral therapy (HAART) has been associated with lipodystrophy (LD) in adults but data are more limited for children. The purpose of this study was to determine the prevalence of and risk factors for LD in Tanzanian children receiving HAART by clinical assessment and to compare the results with anthropometric data. DESIGN AND METHODS: A cross-sectional study was performed in a cohort of HIV-infected children aged 1-18 years receiving HAART in a single center in Moshi, Tanzania. Age, gender, past and current medication regimens and anthropometric measurements were recorded. A clinical scoring method was used to assess LD. Backward binary multivariate logistic regression was used to determine relationships between anthropometric measurements and the presence of clinical LD.
RESULTS: Among 210 HIV-infected children, the prevalence of LD was 30% (95% confidence interval [CI]: 23.8-36.2) overall, 19% (95% CI: 13.7-24.3) for lipoatrophy only, 3.8% (95% CI: 1.2-6.4) for lipohypertrophy only and 7.1% (95% CI: 3.6-10.6) for the mixed type. Most cases were mild. Older age and use of stavudine increased the risk of LD. Overall, the study population was stunted but not underweight. In children with relatively lower weight-for-height (<1), only the mid-upper arm circumference was found to be associated with lipoatrophy, while nearly all anthropometric measurements were associated with lipoatrophy in the well-nourished (weight-for-height ≥1) children.
CONCLUSIONS: Our findings demonstrate that LD is a significant problem among Tanzanian HIV-infected children receiving HAART. Anthropometric measurements predicted LD in well-nourished children but generally failed to do so in relatively wasted children. Our findings support current efforts to avoid stavudine use in children.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23038217     DOI: 10.1097/INF.0b013e3182755a34

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  13 in total

1.  Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.

Authors:  Euden Bhutia; Alok Hemal; Tribhuvan Pal Yadav; K L Ramesh
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

2.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

3.  Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study.

Authors:  Sarah M Ramteke; Stephanie Shiau; Marc Foca; Renate Strehlau; Francoise Pinillos; Faeezah Patel; Avy Violari; Afaaf Liberty; Ashraf Coovadia; Louise Kuhn; Stephen M Arpadi
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-15       Impact factor: 3.164

4.  Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

Authors:  Mutsawashe Bwakura-Dangarembizi; Victor Musiime; Alexander J Szubert; Andrew J Prendergast; Zvenyika A Gomo; Margaret J Thomason; Cuthbert Musarurwa; Peter Mugyenyi; Patricia Nahirya; Adeodata Kekitiinwa; Diana M Gibb; Ann S Walker; Kusum Nathoo
Journal:  Pediatr Infect Dis J       Date:  2015-02       Impact factor: 2.129

5.  Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.

Authors:  Veronica Mulenga; Victor Musiime; Adeodata Kekitiinwa; Adrian D Cook; George Abongomera; Julia Kenny; Chisala Chabala; Grace Mirembe; Alice Asiimwe; Ellen Owen-Powell; David Burger; Helen McIlleron; Nigel Klein; Chifumbe Chintu; Margaret J Thomason; Cissy Kityo; A Sarah Walker; Diana M Gibb
Journal:  Lancet Infect Dis       Date:  2015-10-05       Impact factor: 25.071

Review 6.  Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation.

Authors:  Linda Barlow-Mosha; Victor Musiime; Mary-Ann Davies; Andrew J Prendergast; Philippa Musoke; George Siberry; Martina Penazzato
Journal:  J Int AIDS Soc       Date:  2017-06-27       Impact factor: 5.396

Review 7.  Metabolic complications and treatment of perinatally HIV-infected children and adolescents.

Authors:  Linda Barlow-Mosha; Allison Ross Eckard; Grace A McComsey; Philippa M Musoke
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

8.  Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.

Authors:  Stephanie Shiau; Louise Kuhn; Renate Strehlau; Leigh Martens; Helen McIlleron; Sandra Meredith; Lubbe Wiesner; Ashraf Coovadia; Elaine J Abrams; Stephen M Arpadi
Journal:  BMC Pediatr       Date:  2014-02-12       Impact factor: 2.125

9.  The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children.

Authors:  Rachel C Vreeman; Michael L Scanlon; Megan S McHenry; Winstone M Nyandiko
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

10.  Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland.

Authors:  Steve Innes; Justin Harvey; Intira Jeannie Collins; Mark Fredric Cotton; Ali Judd
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.